Top stories
OSI Pharmaceuticals
USINFO | 2013-08-06 09:53
.png) |
|
| Type | Subsidiary |
| Industry | Biopharmaceuticals &Biotherapeutics[1] |
| Founded | 1983 |
| Headquarters | Melville, New York |
| Key people |
Colin Goddard, CEO Michael G. Atieh, CFO Robert A. Ingram, Chairman[1] |
| Products | Medical Laboratories & Research |
| Revenue | $375.7 MillionUSD(2006)[2] |
| Net income | $-582.2 Million USD(2006)[2] |
| Employees | 554 (2007-02)[3] |
| Parent | Astellas Pharma (2010-present) |
| Website | www.osip.com |
OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. OSI specializes in the discovery and development of molecular targeted therapies. Though oncology is the top priority for OSI, research and development targeting type 2 diabetes and obesity is conducted through their U.K. subsidiaryProsidion Limited.[4][1] OSI has also made a foray into the ophthalmology market through a marketing agreement with Pfizer over Macugen (Pegaptanib) for Age-related macular degeneration; however, acquisition of the firm Eyetech, meant to provide control over this product and diversify the company, has been unsuccessful, ending in divestiture.[5][6]
In mid-2007, OSI's revenues were based primarily on proceeds from Tarceva sales (which are shared with Genentech and Hoffmann–La Roche) and royalty payments related to dipeptidyl-peptidase IVinhibitor intellectual property.[5]
On June 9, 2010, OSI was acquired by Japan-based, TSE-listed Astellas Pharma for $4.0 billion.
Tarceva
See also: ErlotinibTarceva (Erlotinib) was OSI's flagship and, as of 2007, only marketed product.[5][7] Tarceva is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) and is the only EGFR inhibitor to have demonstrated the ability to improve overall survival in advanced non-small cell lung cancer and advanced pancreatic cancer.[4] Tarceva was discovered by Pfizer as CP-358774 (Moyer et al. Cancer Research, 1997, 57:4838), renamed OSI-774 when Pfizer was required to divest the compound in order to complete the buyout of Warner lambert/Parke-Davis and subsequently developed by OSI in conjunction with Genentech.
